UNITÉ DE FABRICATION DES MÉDICAMENTS S.A

Ratings Unité de Fabrication des Médicaments S.A

Equities

UMED

TN0007720014

End-of-day quote Tunis Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
7.09 ^TND	-0.14%		-2.88%	-5.21%

2023	Unité de Fabrication des Médicaments S.A Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	Unité de Fabrication des Médicaments S.A Reports Earnings Results for the Full Year Ended December 31, 2022	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company is one of the best yield companies with high dividend expectations.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The valuation of the company is particularly high given the cash flows generated by its activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
UNITÉ DE FABRICATION DES MÉDICAMENTS S.A	-5.21%	72.64M	-
ELI LILLY AND COMPANY	+31.06%	688B	C+
NOVO NORDISK A/S	+30.35%	588B	B
JOHNSON & JOHNSON	-3.42%	364B	C+
MERCK & CO., INC.	+18.02%	326B	B-
ABBVIE INC.	+4.27%	285B	C+
ASTRAZENECA PLC	+15.53%	239B	B+
NOVARTIS AG	+10.16%	210B	B-
ROCHE HOLDING AG	-8.14%	200B	A+
AMGEN INC.	+8.12%	167B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes